CorMedix (CRMD) Competitors $8.57 -0.30 (-3.38%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRMD vs. AKRO, MIRM, AMPH, TARS, IRON, CGON, HRMY, GLPG, XNCR, and EVOShould you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), CG Oncology (CGON), Harmony Biosciences (HRMY), Galapagos (GLPG), Xencor (XNCR), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. CorMedix vs. Akero Therapeutics Mirum Pharmaceuticals Amphastar Pharmaceuticals Tarsus Pharmaceuticals Disc Medicine CG Oncology Harmony Biosciences Galapagos Xencor Evotec CorMedix (NASDAQ:CRMD) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations. Do institutionals & insiders have more ownership in CRMD or AKRO? 34.2% of CorMedix shares are owned by institutional investors. 5.2% of CorMedix shares are owned by insiders. Comparatively, 7.9% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to CRMD or AKRO? In the previous week, CorMedix and CorMedix both had 10 articles in the media. Akero Therapeutics' average media sentiment score of 0.75 beat CorMedix's score of 0.51 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CRMD or AKRO more profitable? Akero Therapeutics' return on equity of -32.46% beat CorMedix's return on equity.Company Net Margins Return on Equity Return on Assets CorMedixN/A -79.21% -64.68% Akero Therapeutics N/A -32.46%-29.83% Which has better valuation & earnings, CRMD or AKRO? CorMedix has higher revenue and earnings than Akero Therapeutics. CorMedix is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$12.26M42.41-$46.34M-$0.81-10.58Akero TherapeuticsN/AN/A-$151.76M-$3.75-7.82 Does the MarketBeat Community prefer CRMD or AKRO? Akero Therapeutics received 85 more outperform votes than CorMedix when rated by MarketBeat users. However, 74.19% of users gave CorMedix an outperform vote while only 63.53% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformCorMedixOutperform Votes2374.19% Underperform Votes825.81% Akero TherapeuticsOutperform Votes10863.53% Underperform Votes6236.47% Which has more volatility and risk, CRMD or AKRO? CorMedix has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500. Do analysts recommend CRMD or AKRO? CorMedix presently has a consensus price target of $15.80, indicating a potential upside of 84.36%. Akero Therapeutics has a consensus price target of $46.83, indicating a potential upside of 59.62%. Given CorMedix's stronger consensus rating and higher possible upside, equities research analysts clearly believe CorMedix is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 SummaryCorMedix beats Akero Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRMD vs. The Competition Export to ExcelMetricCorMedixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$520.00M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-10.5810.5990.0517.18Price / Sales42.41195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book6.705.094.784.78Net Income-$46.34M$151.83M$120.31M$225.60M7 Day Performance2.27%-2.13%-1.92%-1.23%1 Month Performance-17.04%-3.10%11.51%3.36%1 Year Performance137.40%11.54%30.61%16.60% CorMedix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRMDCorMedix1.8419 of 5 stars$8.57-3.4%$15.80+84.4%+147.0%$520.00M$12.26M-10.5830Analyst ForecastNews CoveragePositive NewsHigh Trading VolumeAKROAkero Therapeutics4.0824 of 5 stars$29.19+1.0%$46.83+60.4%+36.1%$2.04BN/A-7.7030Insider TradeMIRMMirum Pharmaceuticals4.0875 of 5 stars$42.38-0.1%$57.73+36.2%+34.8%$2.03B$307.03M-21.01140Positive NewsAMPHAmphastar Pharmaceuticals4.8626 of 5 stars$41.33-2.2%$60.33+46.0%-33.1%$1.99B$644.40M14.081,761TARSTarsus Pharmaceuticals0.3236 of 5 stars$51.86-1.2%$54.20+4.5%+164.4%$1.98B$17.45M-13.7850Positive NewsIRONDisc Medicine3.4713 of 5 stars$66.57+2.6%$87.50+31.4%+13.2%$1.98BN/A-16.3078Insider TradeCGONCG Oncology2.1551 of 5 stars$28.57-0.7%$63.88+123.6%N/A$1.93B$684,000.000.0061Insider TradeHRMYHarmony Biosciences4.7827 of 5 stars$32.78+1.2%$47.00+43.4%+7.0%$1.87B$681.88M15.35200Analyst ForecastAnalyst RevisionGLPGGalapagos0.6163 of 5 stars$27.00+0.7%$30.75+13.9%-31.4%$1.78B$260.09M0.001,123XNCRXencor4.3204 of 5 stars$25.07+4.3%$36.56+45.8%+18.4%$1.75B$168.34M-7.51280EVOEvotec2.387 of 5 stars$4.69+4.5%$5.93+26.5%-60.5%$1.66B$777.05M0.005,061Positive News Related Companies and Tools Related Companies AKRO Alternatives MIRM Alternatives AMPH Alternatives TARS Alternatives IRON Alternatives CGON Alternatives HRMY Alternatives GLPG Alternatives XNCR Alternatives EVO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRMD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRMD Stock Alerts